BOSTON - Inhaled nitric oxide (NO) can be a valuable adjunct respiratory therapy for pregnant women with severe and critical COVID-19, a team of researchers from Massachusetts General Hospital (MGH) ...

A novel therapy developed at the University of Alabama at Birmingham ameliorates obesity and Type 2 diabetes in mice fed a high-fat diet. The therapy acts through sustained release of nitric oxide, a ...

In a recent article published in Obstetrics & Gynecology, researchers demonstrated that inhaled nitric oxide 200 (iNO 200) enhances oxygenation in pregnant coronavirus disease 2019 (COVID-19) patients ...

WARREN, N.J., April 08, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In pregnant women with severe or critical COVID-19, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Arterial oxygenation in critically ill adults with COVID ...

WARREN, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company focused on developing treatments ...

Inhaled nitric oxide (iNO) therapy is used in neonatal care as a selective pulmonary vasodilator to improve oxygenation and reduce pulmonary vascular resistance. In preterm infants, the application of ...

Mallinckrodt announced that the phase 4 observational registry study evaluating INOmax® (nitric oxide) gas, for inhalation, in preterm neonates with pulmonary hypertension was stopped early due to ...

Healthcare professionals must have a shared understanding of quality and safety considerations when working in neonatal intensive care units, particularly when considering the quality and safety of ...

A first-in-human clinical trial is expected to being in the US in 2026. The Food and Drug Administration (FDA) has granted Orphan Drug designation to BA-102 for the treatment of Phelan-McDermid ...